Showing results (81-90 of 147) with videos related to
Sort By:
Pageof 15
Plos One|July 14, 2011
RTL551 treatment of EAE reduces CD226 and T-bet+ CD4 T cells in periphery and prevents infiltration of T-bet+ IL-17, IFN-γ producing T cells into CNSSushmita Sinha, Lisa M Miller, Sandhya Subramanian, et al.Veterinary and Human Toxicology|April 1, 1993
Effects of hepatic P-450 enzyme inhibitors and inducers on the duration of xylazine + ketamine anesthesia in broiler chickens and miceJ D Roder, R Akkaya, H R Amouzadeh, et al.Journal of Neuroscience Research|July 1, 1997
Multiple class I motifs revealed by sequencing naturally processed peptides eluted from rat T cell MHC moleculesG G Burrows, K Ariail, B Celnik, et al.The Journal of Biological Chemistry|November 25, 1994
Deducing the organization of a transmembrane domain by disulfide cross-linking. The bacterial chemoreceptor TrgG F Lee, G G Burrows, M R Lebert, et al.Journal of Clinical Psychopharmacology|March 29, 2001
Sustained response to open-label venlafaxine in drug-resistant major depressionI Schweitzer, G Burrows, V Tuckwell, et al.Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1984
The effects of benzodiazepines on hormones in women with idiopathic hirsutismL Dennerstein, A Callan, G Warne, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 9, 2005
Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injuryHalina Offner, Sandhya Subramanian, Chunhe Wang, et al.Clinical Immunology (Orlando, Fla.)|January 30, 2007
Monomeric DR2/MOG-35-55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic miceJason M Link, Cathleen M Rich, Maya Korat, et al.Coronary Artery Disease|October 1, 1993
Free radicals, antioxidants, and endothelial cell damage after percutaneous transluminal coronary angioplastyA Blann, H Midgley, G Burrows, et al.Mucosal Immunology|August 26, 2010
Single-chain recombinant HLA-DQ2.5/peptide molecules block α2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac diseaseJ Huan, R Meza-Romero, J L Mooney, et al.Pageof 15